Catalent, Inc. Common Stock, par value $0.01 per share Underwriting AgreementUnderwriting Agreement • February 6th, 2020 • Catalent, Inc. • Pharmaceutical preparations
Catalent, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this underwriting agreement (this “Agreement”), to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters”), for whom J.P. Morgan Securities LLC and UBS Investments LLC are acting as representatives (the “Representatives”), an aggregate of 9,712,837 shares of common stock, par value $0.01 per share (the “Stock”), of the Company. The aggregate of 8,445,946 shares of Stock to be sold by the Company are herein called the “Firm Shares” and the aggregate of up to 1,266,891 additional shares of Stock to be sold by the Company are herein called the “Optional Shares.” The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Shares.” The terms “supplement,” “amendment” and “amend” as used herein with respect to the Registration Statement, the Preliminary Prospectus, the Pr
